Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure

References

• Bernal W, Wendon J. Acute Liver Failure. N Engl J Med. 2013;369(26):2525–2534.
   PubMed Web of Science ®Google Scholar
• McPhail MJ, Kriese S, Heneghan MA. Current management of acute liver failure. Curr Opin Gastroenterol. 2015;31(3):209–214. doi:10.1097/MOG.0000000000000174
   PubMed Web of Science ®Google Scholar
• Takaya H, Yoshiji H, Kawaratani H, et al. Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure. Biomed Rep. 2017;7(3):277–285. doi:10.3892/br.2017.945
   PubMedGoogle Scholar
• Wang LK, Wang LW, Li X, et al. Ethyl pyruvate prevents inflammatory factors release and decreases intestinal permeability in rats with D-galactosamine-induced acute liver failure. Hepatobiliary Pancreat Dis Int. 2013;12(2):180–188. doi:10.1016/s1499-3872(13)60029-6
   PubMed Web of Science ®Google Scholar
• Woodhouse CA, Patel VC, Singanayagam A, et al. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47(2):192–202. doi:10.1111/apt.14397
   PubMed Web of Science ®Google Scholar
• Tomar S, Zumbrun EE, Nagarkatti M, et al. Protective role of cannabinoid receptor 2 activation in galactosamine/lipopolysaccharide-induced acute liver failure through regulation of macrophage polarization and microRNAs. J Pharmacol Exp Ther. 2015;353(2):369–379.
   PubMed Web of Science ®Google Scholar
• van der Heide D, Weiskirchen R, Bansal R. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. Front Immunol. 2019;10:2852. doi:10.3389/fimmu.2019.02852
   PubMed Web of Science ®Google Scholar
• Galvan-Pena S, O’Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol. 2014;5:420. doi:10.3389/fimmu.2014.00420
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553–565.
   PubMed Web of Science ®Google Scholar
• Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed Biotechnol. 2011;2011:371832. doi:10.1155/2011/371832
   PubMedGoogle Scholar
• Farooqi AA, Naqvi SK, Perk AA, et al. Natural Agents-Mediated Targeting of Histone Deacetylases. Arch Immunol Ther Exp (Warsz). 2018;66(1):31–44. doi:10.1007/s00005-017-0488-0
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang Y, Jiao FZ, et al. Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure. Life Sci. 2019;238:116976. doi:10.1016/j.lfs.2019.116976
   PubMed Web of Science ®Google Scholar
• Zhang WB, Yang F, Wang Y, et al. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-kappaB pathways. Biomed Pharmacother. 2019;117:109166. doi:10.1016/j.biopha.2019.109166
   PubMed Web of Science ®Google Scholar
• Zhang WB, Zhang HY, Jiao FZ, et al. Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-kappaB pathway. Biomed Pharmacother. 2018;97:818–824. doi:10.1016/j.biopha.2017.10.103
   PubMed Web of Science ®Google Scholar
• Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature. 2019;573(7775):590–594. doi:10.1038/s41586-019-1551-2
   PubMed Web of Science ®Google Scholar
• Wendon J, Cordoba J, Dhawan, A., et al.; European Association for the Study of the Liver. Electronic address eee, Clinical practice guidelines p. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–1081. doi:10.1016/j.jhep.2016.12.003
   PubMed Web of Science ®Google Scholar
• Zhang WB, Zhang HY, Wang Y, et al. Quantitative proteomic analysis reveals the sites related to acetylation and mechanism of ACY-1215 in acute liver failure mice. Front Pharmacol. 2019;10:653. doi:10.3389/fphar.2019.00653
   PubMed Web of Science ®Google Scholar
• Ryan DG, O’Neill LAJ. Krebs cycle rewired for macrophage and dendritic cell effector functions. FEBS Lett. 2017;591(19):2992–3006. doi:10.1002/1873-3468.12744
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Chen Q, et al. TNF-alpha/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury. Cell Prolif. 2020;53(6):e12829.
   PubMed Web of Science ®Google Scholar
• Ambade A, Satishchandran A, Gyongyosi B, et al. Adult mouse model of early hepatocellular carcinoma promoted by alcoholic liver disease. World J Gastroenterol. 2016;22(16):4091–4108. doi:10.3748/wjg.v22.i16.4091
   PubMed Web of Science ®Google Scholar
• Wu Z, Han M, Chen T, et al. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int. 2010;30(6):782–794. doi:10.1111/j.1478-3231.2010.02262.x
   PubMed Web of Science ®Google Scholar
• Acharya C, Bajaj JS. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am. 2017;46(1):155–169. doi:10.1016/j.gtc.2016.09.013
   PubMed Web of Science ®Google Scholar
• Fukui H. Role of gut dysbiosis in liver diseases: what have we learned so far? Diseases. 2019;7(4). doi:10.3390/diseases7040058
   PubMedGoogle Scholar
• Liu X, Yu L, Hassan W, et al. The duality of Kupffer cell responses in liver metabolic states. Curr Mol Med. 2016;16(9):809–819. doi:10.2174/1566524016666161031143724
   PubMed Web of Science ®Google Scholar
• Mills E, O’Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 2014;24(5):313–320. doi:10.1016/j.tcb.2013.11.008
   PubMed Web of Science ®Google Scholar
• Mills EL, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457–470 e413. doi:10.1016/j.cell.2016.08.064
   PubMed Web of Science ®Google Scholar
• Mills EL, Kelly B, O’Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18(5):488–498. doi:10.1038/ni.3704
   PubMed Web of Science ®Google Scholar
• Moran-Salvador E, Mann J. Epigenetics and liver fibrosis. Cell Mol Gastroenterol Hepatol. 2017;4(1):125–134. doi:10.1016/j.jcmgh.2017.04.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Gong Z. Regulation of acetylation in high mobility group protein B1 cytosol translocation. DNA Cell Biol. 2019;38(5):491–499. doi:10.1089/dna.2018.4592
   PubMed Web of Science ®Google Scholar
• Camell CD, Sander J, Spadaro O, et al. Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing. Nature. 2017;550(7674):119–123. doi:10.1038/nature24022
   PubMed Web of Science ®Google Scholar
• Chan CH, Chen CM, Lee YW, et al. DNA damage, liver injury, and tumorigenesis: consequences of DDX3X loss. Mol Cancer Res. 2019;17(2):555–566. doi:10.1158/1541-7786.MCR-18-0551
   PubMed Web of Science ®Google Scholar
• Fuks F, Burgers WA, Brehm A, et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 2000;24(1):88–91. doi:10.1038/71750
   PubMed Web of Science ®Google Scholar
• Blagitko-Dorfs N, Schlosser P, Greve G, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019;33(4):945–956. doi:10.1038/s41375-018-0293-8
   PubMed Web of Science ®Google Scholar
• Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17(10):630–641. doi:10.1038/nrg.2016.93
   PubMed Web of Science ®Google Scholar
• Mazzone R, Zwergel C, Mai A, et al. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59. doi:10.1186/s13148-017-0358-y
   PubMed Web of Science ®Google Scholar
• Topper MJ, Vaz M, Chiappinelli KB, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284–1300 e1221. doi:10.1016/j.cell.2017.10.022
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127(1):42–52. doi:10.1182/blood-2015-07-604512
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170. doi:10.1038/bcj.2013.68
   PubMed Web of Science ®Google Scholar
• Samanta S, Zhou Z, Rajasingh S, et al. DNMT and HDAC inhibitors together abrogate endotoxemia mediated macrophage death by STAT3-JMJD3 signaling. Int J Biochem Cell Biol. 2018;102:117–127. doi:10.1016/j.biocel.2018.07.002
   PubMed Web of Science ®Google Scholar